BioSpace News Archive

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2020 . Leap First Quarter Highlights: Entered into an exclusive option and license agreement with BeiGene, Ltd. for the clinic

AVROBIO’s optimized lentiviral vectors demonstrate significant glycogen reduction in the muscle and central nervous system of Pompe disease mouse model Investigational New Drug (IND)-enabling proof-of-concept study for AVR-RD-03 for Pompe disease currently underway CAMBRIDGE, Mass.--( BUSINESS WIRE )-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease,

Collaboration to Study Immuno-STAT Biologics on T Cell Immunological Synapse Formation Using the IL-2-Based CUE-100 Series

Continued high rate of SVR35 in 1L patients: 72% at 12 weeks and 67% at 24 weeks SVR35 responses and transfusion dependence conversion observed in 2L monotherapy patients Improvement in bone marrow fibrosis seen across treatment arms Additional data to be presented at EHA from ~50 1L and 70-80 2L patients CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that three abstracts relating to the MANIFEST clinical tr

myCare Studies Show Cellworks Multi-omics Biosimulation is a Superior Predictor of Complete Response to Therapies

Kane Biotech Inc. (TSX-V:KNE), (the “Corporation” or “Kane Biotech”), today announced that it has further amended the terms of its 34,504,997 common share purchase warrants (the “Warrants”) issued on July 17, 2017 (the “Initial Closing”) and August 17, 2017 (the “Final Closing”) pursuant to a private placement of units, by further extending the expiry thereof from July 17, 2020 to January 17, 2022 for the 33,404,997 Warrants issued pursuant

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, today reported an update on the status of COVID-19 infected patients treated with PLX cells under a compassionate use program in Israel and the FDA Single Patient Expanded Access Program in the U.S. All treated patients were in Intensive Care Units (ICU),

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the UBS Virtual Healthcare Conference on Wednesday, May 20, 2020 . Michael Severino , M.D., vice chairman and president and Robert A. Michael , executive vice president and chief financial officer, will present at 9:50 a.m. Central time

First-of-its-kind commercial solution analyzes 3D and sub-surface data 15,000 times faster than a typical Ga-FIB

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infections, announced today that it will present data on AGEN1181 at the American Society of Clinical Oncology (ASCO) upcoming ASCO2020 Virtual Scientific Program to be held May 29-31, 2020 .